Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
8.544B
Avg Qtr Burn
-302M
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zegalogue (Dasiglucagon) Details Hypoglycemia | Approved Quarterly sales | |
Dasiglucagon Details Congenital Hyperinsulinism | NDA Resubmission | |
Glepaglutide Details Short bowel syndrome | NDA Resubmission | |
Survodutide/ BI456906 (GLP-1R/GCGR) Details Non-alcoholic steatohepatitis , metabolic dysfunction-associated steatohepatitis | Phase 3 Data readout | |
Phase 3 Data readout | ||
Dasiglucagon Details Type 1 diabetes | Phase 3 Update | |
Petrelintide (ZP8396) Details Obesity | Phase 2b Data readout | |
Petrelintide (ZP8396) Details Overweight or obesity and type 2 diabetes | Phase 2b Data readout | |
Dapiglutide Details Obesity | Phase 1b Data readout | |
ZP6590 Details Obesity | Phase 1 Initiation | |
Dasiglucagon Details Type 1 diabetes | Failed Discontinued |